Troxacitabine (Shire Pharmaceuticals).
Shire Pharmaceuticals (formerly BioChem Pharma) is developing troxacitabine (Troxatyl), a novel dioxolane nucleoside analog, as a potential treatment for acute myeloid leukemia (AML), pancreatic cancer and solid tumors. Phase I and II clinical studies in patients with pancreatic cancer and AML are in progress.